Janssen

Rybrevant

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Janssen

Rybrevant HCPCS:

J9061

HCPCS Code Descriptor:

Injection, amivantamab-vmjw, 2 mg

Category:

J Code

Rybrevant NDCs:

57894-0501-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Rybrevant CPT Codes:

Potential CPT administration codes for Rybrevant can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Rybrevant:

Rybrevant is an Oncology drug manufactured by Janssen and administered via the Intravenous route of administration. The J Code: J9061 is aligned to the drug Rybrevant.

Rybrevant is a drug used for the treatment of non-small cell lung cancer, or NSCLC, in adults. Rybrevant is approved for patients whose cancer has spread or is unable to be removed surgically, and whose cancer cells have certain genetic changes. Rybrevant may be used when patients have not responded to platinum-based chemotherapy medications. Rybrevant is administered as an infusion.

ACCESS PRICING AND MORE BY REGISTERING

J9061 Added Date:

January 1, 2022

J9061 Effective Date:

January 1, 2022

J9061 Termination Date:

HCPCS Active

Rybrevant billing and coding information can be found through Janssen at the link below:
Rybrevant patient assistance information can be found through the Johnson and Johnson Patient Assistance Foundation at the URL: http://www.jjpaf.org/
Rybrevant prescribing information can be found at the link below:
Information regarding Rybrevant’s side effects can be found at MedlinePlus